Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $133.76 million. The enterprise value is $170.87 million.
| Market Cap | 133.76M |
| Enterprise Value | 170.87M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 43.43 million shares outstanding. The number of shares has increased by 1.45% in one year.
| Shares Outstanding | 43.43M |
| Shares Change (YoY) | +1.45% |
| Shares Change (QoQ) | +1.78% |
| Owned by Insiders (%) | 7.80% |
| Owned by Institutions (%) | 77.58% |
| Float | 35.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.32 |
| PS Ratio | 1.25 |
| Forward PS | 1.14 |
| PB Ratio | 1.94 |
| P/FCF Ratio | 12.37 |
| PEG Ratio | 2.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 78.42, with an EV/FCF ratio of 15.80.
| EV / Earnings | n/a |
| EV / Sales | 1.60 |
| EV / EBITDA | 78.42 |
| EV / EBIT | n/a |
| EV / FCF | 15.80 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.88 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 18.98 |
| Debt / FCF | 3.83 |
| Interest Coverage | -1.45 |
Financial Efficiency
Return on equity (ROE) is -12.00% and return on invested capital (ROIC) is -1.94%.
| Return on Equity (ROE) | -12.00% |
| Return on Assets (ROA) | -6.30% |
| Return on Capital (ROIC) | -1.94% |
| Revenue Per Employee | $256,700 |
| Profits Per Employee | -$20,988 |
| Employee Count | 416 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, HBIO has paid $484,000 in taxes.
| Income Tax | 484,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.84% in the last 52 weeks. The beta is 1.31, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -39.84% |
| 50-Day Moving Average | 3.10 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 49.84 |
| Average Volume (20 Days) | 197,163 |
Short Selling Information
The latest short interest is 534,364, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 534,364 |
| Short Previous Month | 386,199 |
| Short % of Shares Out | 1.23% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 2.42 |
Income Statement
In the last 12 months, HBIO had revenue of $106.79 million and -$8.73 million in losses. Loss per share was -$0.20.
| Revenue | 106.79M |
| Gross Profit | 62.50M |
| Operating Income | -2.13M |
| Pretax Income | -8.25M |
| Net Income | -8.73M |
| EBITDA | 2.18M |
| EBIT | -4.88M |
| Loss Per Share | -$0.20 |
Balance Sheet
The company has $4.26 million in cash and $41.36 million in debt, giving a net cash position of -$37.11 million or -$0.85 per share.
| Cash & Cash Equivalents | 4.26M |
| Total Debt | 41.36M |
| Net Cash | -37.11M |
| Net Cash Per Share | -$0.85 |
| Equity (Book Value) | 68.81M |
| Book Value Per Share | 1.58 |
| Working Capital | 22.47M |
Cash Flow
In the last 12 months, operating cash flow was $13.62 million and capital expenditures -$2.81 million, giving a free cash flow of $10.81 million.
| Operating Cash Flow | 13.62M |
| Capital Expenditures | -2.81M |
| Free Cash Flow | 10.81M |
| FCF Per Share | $0.25 |
Margins
Gross margin is 58.52%, with operating and profit margins of -2.00% and -8.18%.
| Gross Margin | 58.52% |
| Operating Margin | -2.00% |
| Pretax Margin | -7.72% |
| Profit Margin | -8.18% |
| EBITDA Margin | 2.04% |
| EBIT Margin | -4.57% |
| FCF Margin | 10.12% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.45% |
| Shareholder Yield | -1.45% |
| Earnings Yield | -6.53% |
| FCF Yield | 8.08% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 4, 2013. It was a forward split with a ratio of 1319:1000.
| Last Split Date | Nov 4, 2013 |
| Split Type | Forward |
| Split Ratio | 1319:1000 |
Scores
HBIO has an Altman Z-Score of 0.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.55 |
| Piotroski F-Score | 4 |